Els Van Nieuwenhuysen
Overview
Explore the profile of Els Van Nieuwenhuysen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
1714
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee J, Tan D, Ray-Coquard I, Lee J, Kim B, Van Nieuwenhuysen E, et al.
J Gynecol Oncol
. 2024 Dec;
36(1):e51.
PMID: 39710508
Background: Recurrent gynecological clear cell carcinoma (rGCCC) has a low objective response rate (ORR) to chemotherapy. Previous preclinical and clinical data suggest a potential synergy between immune checkpoint inhibitors and...
2.
Yonemori K, Boni V, Min K, Meniawy T, Lombard J, Kaufman P, et al.
Gynecol Oncol
. 2024 Oct;
191:172-181.
PMID: 39442371
Objective: Imlunestrant is a next-generation oral selective estrogen receptor degrader designed to deliver continuous estrogen receptor (ER) target inhibition. EMBER is a phase 1a/b trial of imlunestrant, as monotherapy and...
3.
Grisham R, Monk B, Van Nieuwenhuysen E, Moore K, Fabbro M, OMalley D, et al.
Int J Gynecol Cancer
. 2024 Oct;
PMID: 39375168
Background: There are no approved treatments specifically for low grade serous ovarian cancer; current standard of care treatment options are limited in efficacy and tolerability. The combination of avutometinib with...
4.
Passemiers A, Tuveri S, Sudhakaran D, Jatsenko T, Laga T, Punie K, et al.
Bioinformatics
. 2024 Aug;
40(9).
PMID: 39177091
Motivation: Circulating-cell free DNA (cfDNA) is widely explored as a noninvasive biomarker for cancer screening and diagnosis. The ability to decode the cells of origin in cfDNA would provide biological...
5.
Vergote I, Gonzalez-Martin A, Fujiwara K, Kalbacher E, Bagameri A, Ghamande S, et al.
N Engl J Med
. 2024 Jul;
391(1):44-55.
PMID: 38959480
Background: Recurrent cervical cancer is a life-threatening disease, with limited treatment options available when disease progression occurs after first-line combination therapy. Methods: We conducted a phase 3, multinational, open-label trial...
6.
Ottenbourgs T, Van Nieuwenhuysen E
Cancers (Basel)
. 2024 May;
16(10).
PMID: 38791941
Low-grade serous ovarian cancer (LGSOC) is a rare ovarian malignancy primarily affecting younger women and is characterized by an indolent growth pattern. It exhibits indolent growth and high estrogen/progesterone receptor...
7.
Dareng E, Coetzee S, Tyrer J, Peng P, Rosenow W, Chen S, et al.
Am J Hum Genet
. 2024 May;
111(6):1061-1083.
PMID: 38723632
To identify credible causal risk variants (CCVs) associated with different histotypes of epithelial ovarian cancer (EOC), we performed genome-wide association analysis for 470,825 genotyped and 10,163,797 imputed SNPs in 25,981...
8.
Ottenbourgs T, Van Gorp T, Kridelka F, Baert T, Denys H, Selle F, et al.
Int J Gynecol Cancer
. 2024 Mar;
34(4):627-630.
PMID: 38453176
Background: Low-grade serous and endometrioid ovarian cancers and adult-type granulosa cell tumors are rare ovarian malignancies that show high estrogen receptor positivity. Recurrences of these subtypes of ovarian cancer are...
9.
Westin S, Moore K, Chon H, Lee J, Pepin J, Sundborg M, et al.
J Clin Oncol
. 2023 Oct;
42(3):283-299.
PMID: 37864337
Purpose: Immunotherapy and chemotherapy combinations have shown activity in endometrial cancer, with greater benefit in mismatch repair (MMR)-deficient (dMMR) than MMR-proficient (pMMR) disease. Adding a poly(ADP-ribose) polymerase inhibitor may improve...
10.
Vergote I, Van Nieuwenhuysen E, OCearbhaill R, Westermann A, Lorusso D, Ghamande S, et al.
J Clin Oncol
. 2023 Aug;
41(36):5536-5549.
PMID: 37651655
Purpose: Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab,...